Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Dairy Research Institute | OTHER |
The main objective of this work is to conduct a clinical trial in obese and non-obese individuals testing the ability of low-fat dairy yogurt to improve gastrointestinal health and reduce chronic inflammation. Our central hypothesis is that short and long-term consumption of low-fat dairy yogurt will reduce inflammation to a greater extent in obese individuals by improving intestinal barrier function.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Non-obese individuals | Active Comparator | Daily consumption of 12 oz lowfat yogurt or soy pudding for 9 weeks. |
|
| Obese individuals | Experimental | Consumption of 12 oz of soy pudding or low fat dairy yogurt daily for 9 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Low fat dairy yogurt | Other | Consumption of 12 oz of low fat dairy yogurt daily for 9 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Plasma soluble cluster of differentiation 14 (sCD14) | Fasting plasma sCD14 (change from baseline) | 0, 3, 6, and 9 wk |
| Measure | Description | Time Frame |
|---|---|---|
| Fasting plasma interleukin-6 (IL-6) | Fasting plasma IL-6 (change from baseline) | 0, 3, 6, 9 wk |
| Postprandial sCD14 | Postprandial plasma sCD14 following a high-fat, high-calorie challenge meal (area under curve) |
| Measure | Description | Time Frame |
|---|---|---|
| Fasting lipopolysaccharide binding protein (LBP) | Determined by immunoassay | 0 and 9 wk |
| Fasting plasma endotoxin (LPS, lipopolysaccharide) | Determined by limulus amebocyte lysate assay |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bradley W Bolling, PhD | University of Wisconsin, Madison | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Food Science, Babcock Hall | Madison | Wisconsin | 53706 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29767743 | Derived | Pei R, DiMarco DM, Putt KK, Martin DA, Chitchumroonchokchai C, Bruno RS, Bolling BW. Premeal Low-Fat Yogurt Consumption Reduces Postprandial Inflammation and Markers of Endotoxin Exposure in Healthy Premenopausal Women in a Randomized Controlled Trial. J Nutr. 2018 Jun 1;148(6):910-916. doi: 10.1093/jn/nxy046. | |
| 29179781 | Derived |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007249 | Inflammation |
| D009765 | Obesity |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D050177 | Overweight |
| D044343 | Overnutrition |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Soy pudding | Other | Consumption of 12 oz of low fat soy pudding daily for 9 weeks. |
|
| 0 and 9 wk |
| Postprandial interleukin-6 (IL-6) | Postprandial plasma IL-6 following a high-fat, high-calorie challenge meal (area under curve) | 0 and 9 wk |
| 0, 9 wk |
| Fasting plasma core antibodies to endotoxin | Immunoglobulin M Endotoxin-core antibody (IgM EndoCAb) | 0 and 9 wk |
| Fasting plasma anandamide (AEA) | Determined by LC-MS | 0, 9 wk |
| Fasting plasma 2-arachidonoylglycerol (2-AG) | Determined by LC-MS | 0, 9 wk |
| Fasting plasma IL-10 | Determined by immunoassay | 0, 9 wk |
| Fasting plasma high-sensitivity C-reactive protein (hsCRP) | Determined in fasting plasma | 0, 9 wk |
| Fasting plasma Tumor Necrosis Factor-alpha (TNF-α) | Determined in fasting plasma | 0, 9 wk |
| Fasting plasma Soluble TNF-Receptor II (sTNF-RII) | Determined in fasting plasma | 0, 9 wk |
| TNF-alpha/sTNF-RII ratio | Determined in fasting plasma | 0, 9 wk |
| Fasting plasma glucose | Determined in fasting plasma | 0, 9 wk |
| Fasting plasma triglycerides | Determined in fasting plasma | 0, 9 wk |
| Fasting plasma insulin | Determined in fasting plasma | 0, 9 wk |
| Fasting plasma soluble cluster of differentiation 14 (sCD14) | Determined in fasting plasma | 0, 9 wk |
| Body weight | 0, 3, 6, 9 wk |
| Body mass index | 0, 3, 6, 9 wk |
| Waist circumference | 0, 3, 6, 9 wk |
| Systolic blood pressure | 0, 3, 6, 9 wk |
| Diastolic blood pressure | 0, 3, 6, 9 wk |
| Fasting RPLP0, encoding ribosomal protein large P0 | mRNA expression of peripheral blood mononuclear cell normalized to encoding 18s rRNA (RNA18S5) | 0, 9 wk |
| TLR4, encoding Toll-like receptor 4 | mRNA expression of peripheral blood mononuclear cell normalized to encoding 18s rRNA (RNA18S5) | 0, 9 wk |
| RELA, encoding p65 subunit of nuclear factor kappa B | mRNA expression of peripheral blood mononuclear cell normalized to encoding 18s rRNA (RNA18S5) | 0, 9 wk |
| NFKBIA, encoding nuclear factor kappa B inhibitor alpha | mRNA expression of peripheral blood mononuclear cell normalized to encoding 18s rRNA (RNA18S5) | 0, 9 wk |
| PTGS2, encoding cyclooxygenase-2 (COX-2) | mRNA expression of peripheral blood mononuclear cell normalized to encoding 18s rRNA (RNA18S5) | 0, 9 wk |
| NCF1,encoding the p47 subunit of nicotinamide adenine dinucleotide phosphate-oxidase, (NADPH oxidase) | mRNA expression of peripheral blood mononuclear cell normalized to encoding 18s rRNA (RNA18S5) | 0, 9 wk |
| TNF, encoding tumor necrosis factors (TNF) | mRNA expression of peripheral blood mononuclear cell normalized to encoding 18s rRNA (RNA18S5) | 0, 9 wk |
| IFNG, encoding interferon-γ | mRNA expression of peripheral blood mononuclear cell normalized to encoding 18s rRNA (RNA18S5) | 0, 9 wk |
| TGFB1, encoding transforming growth factor beta 1 (TGFβ1) | mRNA expression of peripheral blood mononuclear cell normalized to encoding 18s rRNA (RNA18S5) | 0, 9 wk |
| Postprandial plasma glucose | Postprandial plasma glucose following a high-fat, high-calorie challenge meal (area under curve) | 0, 9 wk |
| Postprandial plasma triglycerides | Postprandial plasma triglycerides following a high-fat, high-calorie challenge meal (area under curve) | 0, 9 wk |
| Postprandial lipopolysaccharide binding protein (LBP) | Postprandial plasma LBP following a high-fat, high-calorie challenge meal (area under curve) | 0, 9 wk |
| Postprandial lipopolysaccharide (LPS) | Postprandial plasma LPS following a high-fat, high-calorie challenge meal determined by limulus amebocyte lysate assay (area under curve) | 0, 9 wk |
| Postprandial lipopolysaccharide binding protein (LBP)/soluble cluster of differentiation 14 (sCD14) ratio | Postprandial LBP/sCD14 ratio following a high-fat, high-calorie challenge meal (area under curve) | 0, 9 wk |
| Postprandial plasma insulin | Postprandial plasma insulin following a high-fat, high-calorie challenge meal (area under curve) | 0, 9 wk |
| Energy intake (kcal) | Self-reported food intake determined by dietary records | 0, 9 wk |
| Total fat (g) | Self-reported nutrient intake determined by dietary records | 0, 9 wk |
| Carbohydrate (g) | Self-reported nutrient intake determined by dietary records | 0, 9 wk |
| Total protein (g) | Self-reported nutrient intake determined by dietary records | 0, 9 wk |
| Total fat (%) | Self-reported nutrient intake determined by dietary records | 0, 9 wk |
| Carbohydrate (%) | Self-reported nutrient intake determined by dietary records | 0, 9 wk |
| Total protein (%) | Self-reported nutrient intake determined by dietary records | 0, 9 wk |
| Cholestrol (mg) | Self-reported nutrient intake determined by dietary records | 0, 9 wk |
| Saturated fatty acids (g) | Self-reported nutrient intake determined by dietary records | 0, 9 wk |
| Vitamin D (μg) | Self-reported nutrient intake determined by dietary records | 0, 9 wk |
| Calcium (mg) | Self-reported nutrient intake determined by dietary records | 0, 9 wk |
| Sodium (mg) | Self-reported nutrient intake determined by dietary records | 0, 9 wk |
| Potassium (mg) | Self-reported nutrient intake determined by dietary records | 0, 9 wk |
| Total sugars (g) | Self-reported nutrient intake determined by dietary records | 0, 9 wk |
| Added sugars (g) | Self-reported nutrient intake determined by dietary records | 0, 9 wk |
| Pei R, DiMarco DM, Putt KK, Martin DA, Gu Q, Chitchumroonchokchai C, White HM, Scarlett CO, Bruno RS, Bolling BW. Low-fat yogurt consumption reduces biomarkers of chronic inflammation and inhibits markers of endotoxin exposure in healthy premenopausal women: a randomised controlled trial. Br J Nutr. 2017 Dec;118(12):1043-1051. doi: 10.1017/S0007114517003038. Epub 2017 Nov 28. |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |